期刊文献+

研究肿瘤标志物及恶性肿瘤风险指数在诊断盆腔包块良恶性诊断中的应用 被引量:1

下载PDF
导出
摘要 目的研究肿瘤标志物及恶性肿瘤风险指数在盆腔包块良恶性诊断中的应用效果。方法选取108例盆腔包块患者作为观察组,另选取健康检查的108例健康女性作为对照组。对两组进行人绒毛膜促性腺激素(HCG)、糖类抗原125(CA125)检测并比较检测结果 ,分析良恶性盆腔包块患者的恶性肿瘤风险指数。结果观察组良性患者HCG、CA125水平分别为(18.48±2.49)IU/ml、(21.24±4.76)U/ml,恶性患者的HCG、CA125水平分别为(28.66±4.64)IU/ml、(152.35±17.49)U/ml,对照组的HCG、CA125水平分别为(2.35±0.26)IU/ml、(18.68±5.63)U/ml;对照组HCG、CA125水平均明显低于观察组,观察组良性患者HCG、CA125水平明显低于恶性患者,差异均有统计学意义(P<0.05)。108例盆腔包块患者分为高危和低危, 108例盆腔包块患者中68例绝经前患者,其中盆腔包块良性疾病62例,盆腔包块恶性疾病6例;40例绝经后患者,其中盆腔包块良性疾病7例,盆腔包块恶性疾病33例。绝经前6例恶性疾病患者中5例经恶性肿瘤风险指数判定为高危,敏感性为83.33%;62例良性疾病患者中有60例判定为低危,特异性为96.77%。绝经后33例恶性疾病患者中有29例判定为高危,敏感性为87.88%;7例良性疾病患者中有6例判定为低危,特异性为85.71%。结论在盆腔包块良恶性的临床诊断和鉴别中, HCG、CA125两种肿瘤标志物的测定结果可为临床诊断提供科学依据,而采用恶性肿瘤风险指数进行评估可以提高风险预测的敏感性和特异性,值得进一步推广应用。
作者 黄希帆
出处 《中国现代药物应用》 2019年第1期46-47,共2页 Chinese Journal of Modern Drug Application
  • 相关文献

参考文献9

二级参考文献67

  • 1刘伟,李苏宜.卵巢癌化疗新进展[J].肿瘤基础与临床,2006,19(6):526-528. 被引量:19
  • 2Moore RG,Mcmeekin DS,Brown AK,et al. A novel multiple marker bi- oassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass[J]. Gynecol 0ncol,2009,112( 1 ) :40 -46.
  • 3Rosen DG,Wang L,Atkinson JN,et al. Potential markers that comple- ment expression of CA125 in epithelial ovarian cancer [ J ]. Gynecol 0nco1,2005,99 (2) :267 - 277.
  • 4Galgano MT, Hampton GM, Frierson HF, et al. Comprehensive analysis of HFA expression in normal and malignant human tissues [ J ]. Mod Patho1,2006,19 ( 9 ) : 847 - 853.
  • 5Hellstron I, Raycm J, Hayden - Ledbetter M, et al. The HFA ( WFDC2 ) protein is a biomarker for nvallan Carainoa [ J ]. Cancer Res, 2003,63 ( 13 ) :3695 - 3700.
  • 6Montagnana M, Lippi G Ruzzenente O, et al. The utility of serum hu- man epididymis protein4 ( HE4 )in patients with apelvicmass [ J ]. J Clin Lab Anal,2009,23 ( 5 ) :331 - 335.
  • 7Anton C, Carvalho FM, Oliveira EI, et al. A comparison of CA125, HEA, risk ovarian malignancy algorithm (ROMA) , and risk malignancy index (RMI) for the classification of ovarian masses[J]. Clinics ( Sao Paulo), 2012,67 ( 5 ) :437 - 441.
  • 8Sandri MT, Bottari F, Franchi D, et al. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outeome[ J ]. Gynecol Oncol, 2013,128 (2) :233 - 238.
  • 9Karlsen MA, Sandhu N, Hogdall C, et al. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass[J]. Gynecol Oncol, 2012,127(2) :379 -383.
  • 10Havrilesky/d, Whitehead CM, Rubatt JM, et al. Evaluation of biomar- ker panels for early stage ovarian cancer detection and monitoring for disease recurrence [ J ]. Gvnecol Oncol. 2008.110 ( 3 ):374 - 382.

共引文献91

同被引文献9

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部